New drug PEEL-224 takes on advanced cancers in first human trial

NCT ID NCT05329103

First seen May 16, 2026 · Last updated May 16, 2026

Summary

This early study tests a new drug, PEEL-224, for safety and how well it fights tumors in about 65 people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if the drug can shrink tumors. Participants must have good daily function and measurable tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Abramson Cancer Center at Pennsylvania Hospital

    COMPLETED

    Philadelphia, Pennsylvania, 19106, United States

  • Carolina BioOncology Institute

    COMPLETED

    Huntersville, North Carolina, 28078, United States

  • HonorHealth Research Institiute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Huntsman Cancer Institute, University of Utah

    RECRUITING

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Mary Crowley Cancer Research

    COMPLETED

    Dallas, Texas, 75230, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Rhode Island Hospital

    RECRUITING

    Providence, Rhode Island, 02903, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Stanford Cancer Center

    ACTIVE_NOT_RECRUITING

    Palo Alto, California, 94305, United States

Conditions

Explore the condition pages connected to this study.